Search results
- Kyowa Kirin has been growing its North American presence since 2018, which accounted for more than a quarter of Kyowa Kirin’s global revenues in 2022, according to a company press release. The pharmaceutical company established its North American headquarters in New Jersey in July 2023 and has a research facility in La Jolla, California.
People also ask
Who is Kyowa Kirin?
What's new at Kyowa Kirin?
Why should Kyowa Kirin work together?
Where is Kyowa Kirin located?
Learn how our offices in NJ, California and Ontario focus on discovery, product development, and commercialization. Together, we work as a team to understand clinical needs and advance innovations that can have a profound impact on patients’ lives.
- Our People
Kyowa Kirin North America is a tight-knit community that...
- Corporate Compliance
Kyowa Kirin North America’s Comprehensive Compliance...
- Development
Kyowa Kirin Pharmaceutical Pipeline We collaborate with...
- What We Do
Learn how we deliver medicines in the following therapeutic...
- Our Medicines
By clicking the Send button, you authorize Kyowa Kirin,...
- Media Center
Global Life Sciences Company Selects Lee County for First...
- IIS
As part of our commitment to delivering innovative therapies...
- Operations
Kyowa Kirin is planning a new state-of-the-art Global...
- Our People
Jul 11, 2023 · A company with a 70-year history, Kyowa Kirin has been steadily growing its market presence in North America since 2018 when it received approval from the U.S. Federal Drug Administration for the first of three first-in-class medicines it now markets in the United States.
Jul 11, 2023 · A company with a 70-year history, Kyowa Kirin has been steadily growing its market presence in North America since 2018 when it received approval from the U.S. Federal Drug Administration...
Jul 11, 2023 · A company with a 70-year history, Kyowa Kirin has been steadily growing its market presence in North America since 2018 when it received approval from the U.S. Federal Drug Administration for the first of three first-in-class medicines it now markets in the United States.
“Our North American presence continues to grow through strategic investments that are adding new capabilities, new therapeutic expertise, and new talent to our global organization, all in service of meeting patients’ needs,” said Steve Schaefer, President, North America.
Jul 11, 2023 · A company with a 70-year history, Kyowa Kirin has been steadily growing its market presence in North America since 2018 when it received approval from the U.S. Federal Drug Administration for the first of three first-in-class medicines it now markets in the US.
Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory. New Organizational Structure and Senior Leadership Hires Seek to Strengthen Regional Business Operations, Optimize Investments and Aid in Delivery of First-in-Class Medicines.
